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International Society of Nephrology
Any elected member of a national society of nephrology
is eligible for membership in the International Society of
Nephrology, receipt of the Society's official journal,
Kidney International, and participation in the International
Congresses at a reduced registration fee. A subscription
to Kidney International is included in the annual dues of
US $ 33.00. Application forms for membership can be
obtained by writing to Dr. Herman Villarreal, Secretary
General of the International Society of Nephrology,
Departamento de Nefrologia, Instituto Nacional de Cardio-
logia, Avenida Cuauhtemoc 300, Mexico 7, D. F. Checks
for the first year's annual dues should be enclosed (payable
to the International Society of Nephrology).
Meetings
The next meeting of the American Society of Nephrology
will be held on November 19—20, 1973 at the Shoreham
Hotel, Washington, D.C.
The Council on the Kidney in Cardiovascular Disease of
the American Heart Association will hold its Fourth
Annual Postgraduate Seminar on March 12—13, 1973, on
the campus of the University of Pennsylvania, Philadelphia,
Pa. Program Director: Dr. Martin Goldberg. The program
will accent "Drugs, Hormones and the Kidney". Attend-
ance will be limited to 200 registrants. Registration forms
may be obtained from Dr. Alfred M. Bennett, Department
of Councils, American Heart Association, 44 F. 23rd
Street, New York, N.Y. 10010, U.S.A.
There will be a joint meeting of the Italian Society of
Nephrology and the French speaking societies (the French,
Belgian and Swiss Societies of Nephrology) in St. Vincent,
France, on May 26, 1973. The meeting will be devoted
primarily to new information derived from immuno-
fluorescent studies of kidney pathology and the utilization
of optimal methods of communication in nephrology.
Those members who wish to send proposals or suggestions
are invited to write to Prof. A. Vercellone, Ii Segretario,
Societa italiana di Nefrologia, Clinica Medica, Corso
Polonia 14, 10126 Torino.
Style Change for References in Kidney international
Authors should note that the present issue utilizes the
new style for References that was adopted recently by
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Kidney International, All future submissions should
conform to this style. Illustrative examples of the new
style are portrayed in the "Instructions for Authors".
Examinations of the American Board of Internal Medicine
It is planned that the next Subspecialty Areu Examina-
tion in Nephrology will be held October 15, 1974. Applica-
tions for admission should be requested on or about
January 1, 1974, and returned by March 15, 1974.
International Workshop on Risk/Benefit Assessment of
Cyclophosphamide in Renal Disease
An International Workshop was held in New York City
on June 11—13, 1972, to assess the therapeutic index ratio
of cyclophosphamide in patients with renal disease. The
Workshop was organized by the International Study of
Kidney Disease in Children and sponsored jointly by the
Kidney Foundation of New York and the National
Institute of Arthritis and Metabolic Diseases. Almost
forty participants attended. A transcript of the proceedings
is in preparation, but it seemed advisable that some of
the recommendations of the Workshop should be made
known to physicians who may be using cyclophosphamide
in the treatment of renal disease in view of its possible
gonadal toxicity in man.
Clinical data on the effectiveness of cyclophosphamide
in various renal diseases and its toxic effects in man and
experimental animals were reviewed. Committees were
formed to: 1) assess present knowledge of the drug and
make recommendations concerning its use in renal disease;
2) evaluate reports of general toxicity and make recom-
mendations concerning future studies on effectiveness
and toxicity; 3) evaluate present knowledge concerning
gonadal toxicity and make recommendations concerning
present and future evaluations of this problem.
The report of the Committee on General Toxicity will
appear in the full transcript; it will include suggestions
for proposed research needed for clinical appraisal.
The report of the Committee on Gonadal Toxicity in-
cluded information that administration of cyclophos-
phamide in prepubertal children may result in gonadal
damage manifested by sterility as young adults. The
Committee advised an immediate gathering of observations
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n this problem from all major renal clinics throughout
the world, and such a study is underway. Intensified
experimental studies were also recommended.
The Committee on Clinical Use presented recommenda-
tioas which members of the Workshop believe should be
made known prior to publication of the transcript. Its
recommendations were as follows: A) Benefits of cyclo-
phosphamide: 1) it is effective in producing prolonged
remission in steroid-sensitive, frequently relapsing patients
with minimal change histology. Given adequate cyclo-
phosphamide therapy, it appears that 75% will not relapse
within one year and 50% will not relapse for at least two
years after therapy; 2) there is some evidence that some
patients with minimal hange histology who fail to respond
to adequate adrenocorticosteroid therapy may respond
to cyclophosphamide; 3) there is suggestive evidence
that cyclophosphamide may be of benefit in certain
conditions such as Wegener's granulomatosis and S.L.E.
nephritis, but further properly conducted studies are
required. B) Use of cyclophosphamide in renal diseases:
The potential risk and benefit to each patient should be
assessed in the light of information as it becomes available.
In glomerular diseases which are severe and progressive,
the risk to the patient may be such that the potential
hazards of cyclophosphamide are relatively less significant.
Where practicable such patients should be included in
controlled tests. Patients with minimal lesion nephrotic
syndrome, most of whom respond quite well to adreno-
corticosteroids, should not be given cyclophosphamide in
initial treatment. Patients should not be considered resistant
to adrenocorticosteroids until after eight weeks or more
of starting therapy, and cyclophosphamide should not
be given prior to that time. Until the problem of gonadal
toxicity is clarified, cyclophosphamide should not be
used for adrenocorticosteroid-sensitive, frequent relapsers
unless unacceptable steroid toxicity has arisen. If relapse
again occurs after cyclophosphamide therapy has been
given to an adrenocorticosteroid-sensitive patient, a
second course should only be given if steroid toxicity
again obtains. C) Administration of cyclophosphamide:
1) cyclophosphamide should only be given with the in-
formed consent of a patient or parent aware of the potential
risks; 2) long-term cyclophosphamide has been shown
to produce temporary or permanent sterility in males and
females. There is some evidence that in a few instances
long-term therapy of the prepubertal child has caused
permanent sterility. Additional data are required. It is
not known whether the duration of treatment, dosage level,
or both are critical, but in the light of existing information,
it seems prudent that the dose of cyclophosphamide given
should not exceed 60 to 80 days at 2.5 to 3 mg/kg/day
for the child; 3) when cyclophosphamide therapy is
given it is essential to insure an adequate urine flow to
minimize the risk of hemorrhagic cystitis. In the steroid-
sensitive nephrotic, diuresis should be produced with
glucocorticosteroids prior to cyclophosphamide therapy;
4) during cyclophosphamide therapy the patient should
be monitored for alopecia, leucopenia, hematuria and
infection; 5) following cyclophosphamide treatment the
subsequent health of the patient should be watched for at
least a decade if possible. Subsequent sterility, mutagenesis
or carcinogenesis should be recorded. D) Patients formerly
treated: The physician's responsibility to the patient
already treated cannot be overlooked. It seems wise to
inform the patient (or parents) of potential gonadal
damage and to establish the gonadal status if practicable.
It is important not to overlook the psychological implica-
tions of telling a patient or parents of the risk of sterility
which may not be capable of verification or rebuttal for
several years thereafter.
It was emphasized by the committee and the Workshop
as a whole, that the above recommendations represent
the consensus of those who attended the Workshop and
that they are being presented as initial guidelines for
physicians who use cyclophosphamide in the treatment
of patients with renal disease.
